search

All clinical trials

Results 460221-460230 of 470744

Individual Patient Compassionate Use of Nirogacestat

Desmoid TumorNOTCH Gene Mutation Positive Tumors

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.

Available2 enrollment criteria

Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin

Uremic Pruritus

This is an intermediate-size patient population expanded access protocol for the use of intravenous (IV) difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients undergoing hemodialysis.

Approved for marketing11 enrollment criteria

Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009

Breast Neoplasm Malignant Female

Continued access to treatment for subjects who continue benefit from therapy with gedatolisib in combination with palbociclib, and fulvestrant or letrozole.

Available6 enrollment criteria

Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli

The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.

No longer available0 enrollment criteria

A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial...

Lung DiseasesInterstitial (in Pediatric Populations)1 more

This Expanded Access Program (EAP) is intended to facilitate the availability of OFEV® (nintedanib) to children and adolescents with chronic fibrosing interstitial lung disease (ILD) on top of current standard of care treatment and for whom no satisfactory authorized alternative therapy exists and who cannot participate in the ongoing 1199-0378 trial.

Temporarily not available23 enrollment criteria

An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis...

Non-Cystic Fibrosis Bronchiectasis

The purpose of this study is to allow early access to brensocatib for participants with non-cystic fibrosis bronchiectasis (NCFBE) who have successfully completed the INS1007301 ASPEN Clinical trial.

Available11 enrollment criteria

MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Polycythemia Vera

The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with Polycythemia Vera. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Available20 enrollment criteria

Comparison of Clinical and Radiological Results of Using Only Screws and Plate Use in Latarjet Operation...

Shoulder Dislocation

Randomized controlled comparison of the clinical and radiological results of using only screws and plate use in latarjet surgery in shoulder instability

Temporarily not available3 enrollment criteria

Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil...

Thyroid Cancer

This is an Expanded Access Program to make lenvatinib available to participants with radioiodine-refractory differentiated thyroid cancer in Brazil. Participants who have no other treatment options available, and who, in the opinion and clinical judgment of the treating physician, would benefit from treatment with lenvatinib will be enrolled. This is a multicenter, open-label program consisting of 2 phases: a 28-day pretreatment phase (including screening) and a treatment phase. Treatment will be provided as long as there is a clinical benefit based on tumor assessments performed according to the center's standard of care and the judgment of the participant's treating physician.

Approved for marketing34 enrollment criteria

MLN8237 for a Subject With Adenocarcinoma of the Prostate

Prostate Cancer

To allow a patient continued access to MLN8237

No longer available44 enrollment criteria
1...460224602346024...47075

Need Help? Contact our team!


We'll reach out to this number within 24 hrs